ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

11/10/2014 - 3 minutes

ARTES BiotechnologyInstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary applications.

Nowadays virus-like particles (VLPs) have become a widely used vehicle for the development of vaccines used in humans. Without being infectious, the particles are used to transport foreign antigens in an ideal way to the immune system. For veterinary applications, the applied VLP production process needs to be simplified and optimized. The platform technology and the common production process requires adaption in reference to cost-effectiveness and promptness. Especially the factor “manufacturing cost” is the major driver for a successful market introduction and will influence the acceptance for later necessary mass vaccinations in the veterinary field.

The intent of “Plurivax” is to develop a stable production platform and an adapted high-quality process to have an effective and usable integrated best practice suitable for several veterinary vaccines.

The platform resulting from this project will be the first of its kind in veterinary application and thus opens access to a huge market.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member